Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 669

1.

Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC; Chinese Coronary Secondary Prevention Study Group.

J Clin Pharmacol. 2009 Aug;49(8):947-56. doi: 10.1177/0091270009337509.

PMID:
19602720
3.

Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC; Chinese Coronary Secondary Prevention Study Group.

Ann Med. 2010 Apr;42(3):231-40. doi: 10.3109/07853891003652534.

PMID:
20350253
4.

Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).

Zhao SP, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC, Liu L, Ye HJ, Wu ZH; China Coronary Secondary Prevention Study (CCSPS).

J Cardiovasc Pharmacol. 2007 Feb;49(2):81-4.

PMID:
17312447
5.

Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS).

Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC; Chinese Coronary Secondary Prevention Study (CCSPS) Group.

Clin Exp Hypertens. 2010;32(8):491-8. doi: 10.3109/10641961003686427.

PMID:
21091365
6.

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.

Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group, Li S.

Am J Cardiol. 2008 Jun 15;101(12):1689-93. doi: 10.1016/j.amjcard.2008.02.056. Epub 2008 Apr 11.

PMID:
18549841
7.

[China coronary secondary prevention study (CCSPS)].

Lu ZL; Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang.

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Feb;33(2):109-15. Chinese.

PMID:
15924803
8.

[China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].

Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC; Collaborative Group of China Coronary Secondary Prevention Study.

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1067-70. Chinese.

PMID:
16563271
10.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Drugs. 2004;64 Suppl 2:43-60.

PMID:
15765890
11.

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group.

Diabetes Care. 2003 Oct;26(10):2713-21.

PMID:
14514569
12.

[China coronary secondary prevention study: analysis of patients with different myocardial infarction history].

Du BM, Lu ZL, Chen Z, Wu YF, Zhao WD, Huang TG; Collaborative Group of China Coronary Secondary Prevention Study.

Zhonghua Nei Ke Za Zhi. 2006 Jan;45(1):21-4. Chinese.

PMID:
16624082
13.
15.

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)

Sacks FM, Pfeffer MA, Moye' L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E.

Am J Cardiol. 1991 Dec 1;68(15):1436-46. Erratum in: Am J Cardiol 1992 Feb 15;69(5):574.

PMID:
1746424
16.
17.

Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey.

Sicard P, Zeller M, Dentan G, Laurent Y, Touzery C, L'huillier I, Janin-Manificat L, Lorgis L, Beer JC, Makki H, Rochette L, Cottin Y; RICO survey working group.

Am J Hypertens. 2007 Nov;20(11):1133-9.

PMID:
17954357
18.

Beta-blockers: primary and secondary prevention.

Cruickshank JM.

J Cardiovasc Pharmacol. 1992;20 Suppl 11:S55-69. Review.

PMID:
1284145
19.

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Bybee KA, Lee JH, O'Keefe JH.

Curr Med Res Opin. 2008 Apr;24(4):1217-29. doi: 10.1185/030079908X292001 . Epub 2008 Mar 20. Review.

PMID:
18358084
20.

[The best of epidemiology and cardiovascular prevention in 2006].

Thomas D, Collet JP, Cottin Y, Cournot M, Ducimetière P, Ferrières J, Paillard F, Valensi P, Zeller M, Cambou JP.

Arch Mal Coeur Vaiss. 2007 Jan;100 Spec No 1:57-64. Review. French.

PMID:
17405566
Items per page

Supplemental Content

Write to the Help Desk